30 Day Trial

Centinel Spine Marks 18 Years of prodisc L Use in the U.S.

Share:

Centinel Spine announced the milestone of the 18th year of clinical usage of the prodisc® L Lumbar total disc replacement (TDR) in the U.S. The device was first implanted in the U.S. by Jack Zigler, M.D., during concurrent Investigational Device Exemption studies to gain FDA approval for one- and two-level use. 

Use of prodisc L has grown nearly 40% over the last year due to expanded insurance carrier approvals. Most recently UnitedHealthcare and TRICARE, have changed coverage decisions to enable reimbursement for the device.

Centinel Spine recently celebrated 30 years of the use of prodisc technology ex-U.S.. The entire prodisc line comprises six devices, including an anterior and anterior-lateral approach lumbar disc replacement and four cervical discs with varying endplate configurations. Newer developments include a clinical trial comparing the prodisc C Vivo and prodisc C SK™ devices with an approved cervical TDR product as control.

"prodisc's longevity substantiates its design principles; to provide a stable bone interface coupled with a mechanism of action enabling guided motion," said Centinel Spine Chairman & CEO, John Viscogliosi. "Kudos to Dr. Zigler for recognizing the advantages of this technology 18 years ago, and my thanks for his continued support in educating about prodisc technology in the years since his landmark first implantation."

Centinel Spine prodisc-L - ORTHOWORLD

Sources: Centinel Spine, LLC; ORTHOWORLD Inc.